Janux Therapeutics’ (JANX) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Janux Therapeutics (NASDAQ:JANX) in a research report report published on Thursday morning,Benzinga reports. HC Wainwright currently has a $63.00 price target on the stock.

JANX has been the topic of a number of other reports. Stifel Nicolaus began coverage on shares of Janux Therapeutics in a research note on Friday, September 6th. They set a “buy” rating and a $70.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $100.00 price target on shares of Janux Therapeutics in a research report on Thursday. UBS Group assumed coverage on Janux Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $69.00 price objective for the company. Wedbush reaffirmed an “outperform” rating and set a $74.00 target price on shares of Janux Therapeutics in a report on Thursday, August 8th. Finally, Scotiabank decreased their target price on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a research report on Friday, August 9th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, Janux Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $66.44.

Janux Therapeutics Trading Down 0.5 %

NASDAQ:JANX opened at $53.92 on Thursday. Janux Therapeutics has a one year low of $5.65 and a one year high of $65.60. The business’s 50-day simple moving average is $49.02 and its 200 day simple moving average is $46.35.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). The business had revenue of $0.44 million during the quarter, compared to analyst estimates of $1.50 million. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The firm’s revenue for the quarter was down 82.6% on a year-over-year basis. Sell-side analysts forecast that Janux Therapeutics will post -1.29 earnings per share for the current year.

Insider Activity

In related news, CEO David Alan Campbell sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $53.54, for a total value of $1,338,500.00. Following the sale, the chief executive officer now owns 282,054 shares of the company’s stock, valued at approximately $15,101,171.16. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Janux Therapeutics news, major shareholder Ventures Xi L.P. Avalon sold 2,182 shares of the business’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $42.33, for a total transaction of $92,364.06. Following the completion of the transaction, the insider now directly owns 7,000 shares of the company’s stock, valued at $296,310. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO David Alan Campbell sold 25,000 shares of the company’s stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $53.54, for a total transaction of $1,338,500.00. Following the completion of the transaction, the chief executive officer now owns 282,054 shares of the company’s stock, valued at approximately $15,101,171.16. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 420,610 shares of company stock valued at $19,288,666. 29.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Janux Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Janus Henderson Group PLC increased its position in Janux Therapeutics by 1.8% in the 1st quarter. Janus Henderson Group PLC now owns 1,965,546 shares of the company’s stock valued at $73,961,000 after acquiring an additional 34,069 shares during the period. Price T Rowe Associates Inc. MD acquired a new position in shares of Janux Therapeutics during the first quarter valued at $739,000. Virtu Financial LLC acquired a new position in shares of Janux Therapeutics during the first quarter valued at $609,000. Vanguard Group Inc. raised its stake in shares of Janux Therapeutics by 38.6% during the first quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock valued at $51,127,000 after purchasing an additional 378,477 shares in the last quarter. Finally, Blue Owl Capital Holdings LP acquired a new stake in Janux Therapeutics in the second quarter worth about $1,676,000. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.